Abstract | BACKGROUND: PROCEDURE: RESULTS: At the time of the report, 19 patients were alive and without evidence of disease. Six developed distant metastases (one associated with local recurrence); five of them died of their disease and one was alive in complete remission at 4 years from relapse. With a median follow-up of 9 years (range 2-23), the survival and the event-free survival at 5 years were 80% (SE 8.2) and 74% (SE 9.2), respectively. All relapsing patients had been classified as T2B. CONCLUSIONS: Multimodality treatment yielded satisfying survival results using limb-preserving surgery in most cases. Tumor size > 5 cm and invasiveness, which defined stage T2B, were the most important predictors of poor outcome. Evaluation of the role of adjuvant chemotherapy and radiotherapy awaits prospective studies, even if T2B patients, as well as children having nonradical surgery, seem worth managing by adjuvant treatments.
|
Authors | A Ferrari, M Casanova, M Massimino, R Luksch, G Cefalo, F Lombardi, S Galimberti, G Riganti, F Fossati-Bellani |
Journal | Medical and pediatric oncology
(Med Pediatr Oncol)
Vol. 32
Issue 1
Pg. 32-7
(Jan 1999)
ISSN: 0098-1532 [Print] United States |
PMID | 9917750
(Publication Type: Journal Article)
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Arm
(radiation effects, surgery)
- Chemotherapy, Adjuvant
- Child
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Leg
(radiation effects, surgery)
- Male
- Neoplasm Invasiveness
- Neoplasm Recurrence, Local
(pathology)
- Neoplasm Staging
- Radiotherapy Dosage
- Radiotherapy, Adjuvant
- Reoperation
- Retrospective Studies
- Sarcoma, Synovial
(drug therapy, radiotherapy, secondary, surgery)
- Survival Rate
- Treatment Outcome
|